Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

CAMP vs STTK: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

STTK Captures Overall Composite Edge (52.1 HOLD vs 41.9 SELL), While CAMP Leads 3–2 on Growth & Valuation Pillars

STTK Overall Winner 6-Pillar Tally: CAMP 3 – 2 STTK (1 Tie) Matrix Metrics: CAMP 1 – 6 STTK

As of Nov 17, 2026, Shattuck Labs, Inc. (STTK) captures the overall head-to-head institutional edge over CAMP4 Therapeutics Corporation (CAMP) on higher Unified Composite conviction (52.1/100 HOLD vs. 41.9/100 SELL) after splitting the core matrix 6–1 (led by Profitability & Quality, Options & Positioning), while CAMP wins 3–2 across the 6-pillar growth and valuation breakdown. CAMP trades at $3.95 (N/M Forward P/E, -991.8% operating margin) versus STTK at $4.52 (N/M Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: STTK earns the overall head-to-head edge with a stronger Unified Composite Score (52.1/100 HOLD vs. CAMP 41.9/100 SELL) and 1.45β · 76% Vol risk profile, whereas CAMP leads top-line expansion (+138.9% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: CAMP trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 53.3); meanwhile STTK is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 35.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CAMP vs STTK
CAMP NASDAQ
CAMP4 Therapeutics Corporation Common Stock
Pharmaceutical Preparations
$3.95
+2.33% 1D
Market Cap $238.5M
TTM Revenue $5.3M
Forward P/E N/M
Beta / 30D Vol 1.34β · 94% Vol
Unified Composite Score
41.9 / 100 SELL
Tech 30.0 Fund 40.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 53
RSI-14: 53.3 · SMA20: $3.82 · SMA50: $3.84
STTK NASDAQ Head-to-Head Winner
Shattuck Labs, Inc. Common Stock
Pharmaceutical Preparations
$4.52
-3.0% 1D
Market Cap $473.6M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.45β · 76% Vol
Unified Composite Score
52.1 / 100 HOLD
Tech 57.0 Fund 57.0 Flow 63.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -13.0%), weak momentum, RSI 35
RSI-14: 35.2 · SMA20: $5.18 · SMA50: $5.71

6-Pillar Scorecard Institutional Category Breakdown (CAMP 3 – 2 STTK)

Columns: Metric · CAMP · STTK
1. Valuation Multiples CAMP
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 26.6x N/M
2. Growth & Scale CAMP
Revenue Growth (YoY) +138.9% -66.6%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $5.3M N/A
Market Cap $238.5M $473.6M
3. Profitability & Quality STTK
Gross Margin N/A N/A
Operating Margin -991.8% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -146.1% -47.2%
4. Balance Sheet & Cash Flow CAMP
Cash Generation (TTM) -$26M -$50M
Cash Flow Margin N/A N/A
Net Cash / Leverage $97M Net Cash $59M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning STTK
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 72.4% (10th %ile)
Put/Call OI Skew N/A 4.54x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CAMP (1) vs STTK (6)
Institutional Metric CAMP STTK Criterion Row Edge
Market Capitalization
Scale
$238.5M $473.6M Larger Scale STTK
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+138.9% -66.6% Higher Growth CAMP
Operating Margin (TTM)
Profitability
-991.8% 0.0% Higher Margin STTK
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-146.1% -47.2% Higher ROE STTK
52-Week Range Position
Momentum
22% ($3–$8) 42% ($2–$8) Stronger Trend STTK
Beta / 30D Volatility
Risk Regime
1.34β · 94% Vol 1.45β · 76% Vol Lower Realized Risk STTK
Unified Institutional Score
Composite Signal
41.9 / 100 (SELL) 52.1 / 100 (HOLD) Higher Composite STTK
Trailing 12M Revenue (USD)
Operating Scale
$5.3M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 26.6x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$26M ($97M Net Cash) -$50M ($59M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CAMP +41.63 pp
CAMP: +25.8% · STTK: -15.83%
3M Horizon CAMP +25.94 pp
CAMP: -15.05% · STTK: -40.99%
6M Horizon CAMP +17.11 pp
CAMP: -4.82% · STTK: -21.93%
1Y Horizon STTK +144.09 pp
CAMP: -3.66% · STTK: +140.43%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period CAMP Revenue STTK Revenue CAMP Op. Margin STTK Op. Margin Margin Leader
FY2019 N/A $10M N/A -253.5% STTK
FY2020 N/A $10M N/A -371.8% STTK
FY2021 N/A $30M N/A -150.8% STTK
FY2022 N/A $0M N/A -15848.0% STTK
FY2023 $0M $0M -14822.6% -5549.6% STTK
FY2024 $0M $10M -8142.3% -1408.3% STTK
FY2025 $0M $0M -1502.4% -5150.8% CAMP

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CAMP UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CAMP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
STTK BREAKDOWN
59d in phase · OBV NEUTRAL
Current IV 72.4%
IV Percentile 10th %ile
Put/Call OI Skew 4.54x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact STTK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CAMP Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $238.5M market capitalization and -991.8% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
STTK Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $473.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CAMP vs STTK Key Questions & Quantitative Answers

As of Nov 17, 2026, Shattuck Labs, Inc. (STTK) captures the overall head-to-head institutional edge over CAMP4 Therapeutics Corporation (CAMP) on higher Unified Composite conviction (52.1/100 HOLD vs. 41.9/100 SELL) after splitting the core matrix 6–1 (led by Profitability & Quality, Options & Positioning), while CAMP wins 3–2 across the 6-pillar growth and valuation breakdown. CAMP trades at $3.95 (N/M Forward P/E, -991.8% operating margin) versus STTK at $4.52 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: STTK earns the overall head-to-head edge with a stronger Unified Composite Score (52.1/100 HOLD vs. CAMP 41.9/100 SELL) and 1.45β · 76% Vol risk profile, whereas CAMP leads top-line expansion (+138.9% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: CAMP trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 53.3); meanwhile STTK is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 35.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CAMP leads the Growth & Scale pillar: CAMP posts +138.9% YoY revenue growth and +0.0% YoY earnings growth on $5.3M TTM revenue (N/A gross margin, -991.8% operating margin), compared with STTK at -66.6% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), CAMP cumulative revenue shifted N/A while STTK shifted +0.0%. In operating R&D and SG&A reinvestment, CAMP deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for STTK.

CAMP screens cheaper on headline valuation multiples. CAMP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 26.6x EV/Revenue (unreported FCF margin), whereas STTK trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CAMP (-146.1% ROE) versus STTK (-47.2% ROE) capital efficiency.

In options market volatility and institutional positioning, CAMP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.34β · 94% Vol realized risk). By comparison, STTK carries 72.4% implied volatility (10th %ile, Compressed (<25th %ile)), a 4.54x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.45β · 76% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.